Cart is empty
Contains therapeutic doses of a combination of 6 homocysteine-reducing nutrients: folate, vitamins B2, B6 and B12, inositol and zinc. Homocysteine is naturally produced by the body. Elevated homocysteine is associated with cardiovascular disease. However, research is unclear whether homocysteine is a cause of cardiovascular disease, or if it is a marker (effect) of existing cardiovascular disease. Folate is proven to reduce homocysteine levels. Research published in the medical journal, Stroke, indicates that folic acid may reduce the risk of strokes, an effect which may be independent of its effect on homocysteine. Elevated homocysteine has also been noted in some cancers, but it is too early to know if reducing homocysteine will protect against cancer.
Homocysteine is naturally produced in the body. Elevated homocysteine is associated with cardiovascular disease. However, research is unclear whether homocysteine is a cause of cardiovascular disease. Folic acid is proven to reduce homocysteine levels. Research published in the medical journal Stroke, indicates that folic acid may reduce the risk of strokes, an effect that may be independent of its effect on homocysteine.
Each capsule contains the following as active ingredients:
Folate (L-5-methyltetrahydrofolate calcium) 750µg
Vitamin B12 (methylcobalamin form) 1.5mg
Vitamin B6 (pyridoxa-5-phosphate) 100mg
Vitamin B2 (riboflavin-5-phospate) 20mg
Zinc (zinc amino acid chelate) 20mg
Inactive ingredients: Hypromellose (cellulose) vegetarian capsule shell (gelatine free), microcrystalline cellulose, magnesium stearate (vegetarian - flow agent), magnesium silicate, silicon dioxide and colloidal silicon dioxide. Contains plant extracts and natural fillers, with no colourants added – therefore the colour of the capsule contents may vary slightly from batch to batch.
Store in a cool dry place, below 25°C. Keep out of the reach of children.
Homocysteine is an amino acid commonly found in the blood. High levels of homocysteine has been identified as a risk factor for coronary, cerebral, and peripheral atherosclerosis; recurrent thromboembolism; deep vein thrombosis; myocardial infarction; and ischemic stroke. Low serum folate levels (less than 9.9 nmol/L) and low dietary folate intake (less than 211 mcg per day) are also associated with an increased risk for acute coronary events and cardiovascular disease mortality. A 5 micromole increase in plasma homocysteine increases the risk of cerebrovascular disease by 50%, and the risk of coronary heart disease by 60% in men and 80% in women. Other evidence suggests that homocysteine may have an effect on atherosclerosis by damaging the inner lining of arteries and promoting blood clots. Plasma homocysteine levels are also strongly influenced by diet and genetic factors. Homocysteine Lowering Formula has been scientifically formulated to provide proven homocysteine reducing nutrients at optimal doses. These nutrients work in two ways to metabolise homocysteine: by trans-sulferation and remethylation. Folic acid, zinc and vitamin B12 are cofactors that are required for the remethylation of homocysteine back to methionine. Trans-sulfuration of homocysteine results in degradation of homocysteine to cystathionine and then to cysteine by vitamin B6 dependent enzymes. Vitamin B2 has also been shown to reduce homocysteine levels significantly.
Adult: Take 1 capsule daily or as advised by your healthcare provider. It is recommended to use SOLAL’s TMG in conjunction with this product.
Do not exceed recommended dosages unless on the advice of a health care provider. Do not use this product if you are allergic to any of the ingredients. If you are on any medication or suffering from any medical condition, it is advisable to seek medical advice before starting any new medicine, supplement or remedy. Safety in children has not been established.
Homocysteine Lowering Formula is generally well tolerated. The following rare side effects have been reported: abdominal cramps, dizziness, diarrhoea and rash.
Phenytoin: Folic acid may be a cofactor in phenytoin metabolism. Methotrexate: Prevents the conversion of folic acid into its active form. Phenobarbital: Folic acid can reverse the effects of phenobarbital and weaken the seizure control, use under the supervision of a medical practitioner. Oral contraceptives: May interfere with the absorption of riboflavin.
Pregnancy & Breastfeeding
Safety in pregnancy and breastfeeding has not been established.